| Line | All comers | Risk group |
|---|
| Screening, prevention and diagnosis | 1 | · |
| Early / localised | 1 | 1 |
| Special situations | 1 | · |
| Other settings | 2 | · |
Screening, prevention and diagnosis
| Subgroup | Setting | Approach | Products and trials | Guideline | Evidence |
|---|
| All comers | Prevention and detection | HPV vaccination and HPV-based screening with colposcopy for positives. | | | 90 |
Early / localised
| Subgroup | Setting | Approach | Products and trials | Guideline | Evidence |
|---|
| All comers | Adjuvant after surgery | Pelvic radiotherapy for intermediate-risk features; cisplatin chemoradiation for positive nodes, margins or parametria. | | | 93 |
| Risk group | Stage IA2 to IB1 up to 2 cm, low risk | Simple hysterectomy with node assessment (SHAPE) or open radical hysterectomy; sentinel node biopsy where a trial or protocol supports it. | | | 83 |
Special situations
| Subgroup | Setting | Approach | Products and trials | Guideline | Evidence |
|---|
| All comers | Fertility preservation | Cone or simple trachelectomy for IA disease; radical trachelectomy with node assessment for IB1 tumours up to 2 cm. | | | 83 |
Other settings
| Subgroup | Setting | Approach | Products and trials | Guideline | Evidence |
|---|
| All comers | Stage IA1 without lymphovascular invasion | Cone biopsy with clear margins or simple hysterectomy; no node assessment needed. | | | 40 |
| All comers | Stage IB1 to IB2, standard | Open radical hysterectomy with pelvic lymphadenectomy; minimally invasive radical hysterectomy avoided after LACC. | | | 48 |
Sequence and caution pairings
Lines and subgroups are parsed from the setting text of each standard-of-care row and can misclassify an unusual phrasing; the row’s own setting is always shown. Guideline chips reflect the NCCN category and ESMO-MCBS grade recorded on the cancer page, checked on its stated date. Not medical advice.